StockSelector.com
  Research, Select, & Monitor Saturday, July 21, 2018 1:25:45 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Cymabay Therapeutics, Inc.$12.40($.40)(3.13%)

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Cymabay Therapeutics, Inc. has an overall rank of 6535 out of 7039 stocks based on 5 positive rankings and 10 negative rankings.

Positive Rankings
Target Prices
The average analysts' target price is $23.00 for Cymabay Therapeutics using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Cymabay Therapeutics is ranked 54.
Oversold Stochastics
Cymabay Therapeutics rank is 86
Historic Revenue Growth
Cymabay Therapeutics rank is 455
Debt-to-Equity
Cymabay Therapeutics rank is 502
Low Put/Call
Cymabay Therapeutics has a low Put/Call ratio of 0.42 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Cymabay Therapeutics is ranked 874.
Negative Rankings
Price-to-Sales
Cymabay Therapeutics rank is 98
Negative Net Margin
Cymabay Therapeutics rank is 208
10 Day Loss
Cymabay Therapeutics rank is 302
Down Ratings Revision
During the past month, the average analyst's rating or recommendation has decreased. Among companies that have been downgraded within the past month, Cymabay Therapeutics is ranked 348.
Price-to-Book
Cymabay Therapeutics rank is 565
Negative ROE
Cymabay Therapeutics rank is 746
Negative ROA
Cymabay Therapeutics rank is 793
High vPut/Call
Cymabay Therapeutics has a high Put/Call ratio of 0.98 on active options expiring within the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Cymabay Therapeutics is ranked 900.
90 Day Loss
Cymabay Therapeutics rank is 1119
Down EPS Surprise
Cymabay Therapeutics missed the consensus earnings estimate when it last reported quarterly earnings.







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2018 StockSelector.com. All rights reserved.